Abstract
Leflunomide belongs in the group of disease-modifying anti-rheumatic drugs (DMARDs) used in the treatment of psoriatic, rheumatoid, and reactive arthritis. Approximately 20 % of patients will experience some adverse event, mainly weight loss, abdominal pain, and diarrhea. We describe the clinical, endoscopic, and histological findings in a patient with psoriatic arthritis (PA) who developed severe chronic diarrhea after drug use.
| Original language | English |
|---|---|
| Pages (from-to) | 735-736 |
| Number of pages | 2 |
| Journal | Revista Espanola de Enfermedades Digestivas |
| Volume | 113 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2021 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Chronic diarrhea
- Collagenous colitis
- Leflunomide
Fingerprint
Dive into the research topics of 'Leflunomide as a cause of collagenous colitis: An entity to consider'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver